Anavex Life Sciences Corp.
AVXL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001314052
No open-market purchases or sales by Anavex Life Sciences Corp. insiders were filed in the last 90 days; 180 institutions reported holding it in 13F filings for Q2 2026, worth $95.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Anavex Life Sciences Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Anavex Life Sciences Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Missling Christopher U | President and CEO | 1,510,165 | Jan 9, 2026 | 2 |
| Boenisch Sandra | PFO & Treasurer | 22,963 | Jan 9, 2026 | 2 |
| Thomas Steffen | Director | 43,651 | Jun 9, 2025 | 0 |
| Skarpelos Athanasios | Director | 1,306,458 | Apr 2, 2025 | 0 |
| Donhauser Peter D.O. | Director | 5,000 | Apr 2, 2025 | 0 |
| Velden Claus Vander | Director | – | Apr 2, 2025 | 0 |
| Ma Jiong | Director | – | Apr 2, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2024 (view filing) | Jun 14 | 3 days | Donhauser Peter D.O.Director | PPurchase | +2.83K | $3.64 | +$10.3K | +130.9%5.00K after | |
| May 17, 2024 (view filing) | May 15 | 2 days | Thomas SteffenDirector | PPurchase | +5.00K | $4.52 | +$22.6K | New position5.00K after | |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | Missling Christopher UPresident and CEO | SSale | −73.4K | $5.11 | −$375.0K | −5.5%1.25M after | |
| Jun 30, 2023 (view filing) | Jun 28 | 2 days | Missling Christopher UPresident and CEO | SSale | −268.0K | $7.98 | −$2.14M | −20.8%1.02M after | |
| May 27, 2022 (view filing) | May 25 | 2 days | Skarpelos AthanasiosDirector | SSale | −50.0K | $9.06 | −$453.0K | −3.7%1.31M after | |
| Jul 1, 2021 (view filing) | Jun 29 | 2 days | Missling Christopher UPresident and CEO | SSale | −51.6K | $26.00 | −$1.34M | −4.8%1.02M after | |
| Jul 1, 2021 (view filing) | Jun 29 | 2 days | Boenisch SandraPFO and Treasurer | SSale | −166.7K | $26.53 | −$4.42M | −87.9%23.0K after |